Update on anti-CTLA-4 antibodies in clinical trials
| Autor: | Timothy M. Clay, Lee Langer, Michael A. Morse |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Pharmacology
business.industry medicine.drug_class medicine.medical_treatment Clinical Biochemistry Ipilimumab Immunotherapy Monoclonal antibody Antigens Differentiation Immune tolerance Immune system Antigen Antigens CD CTLA-4 Drug Discovery Immunology medicine Animals Humans CTLA-4 Antigen Antibodies Blocking business Tremelimumab Randomized Controlled Trials as Topic medicine.drug |
| Zdroj: | Expert Opinion on Biological Therapy. 7:1245-1256 |
| ISSN: | 1744-7682 1471-2598 |
| Popis: | Breaking immune tolerance against tumor self-antigens is presently an area of intense research in the design of cancer therapies. One possible method to enhance immune system activation against tumor antigens is by blocking the inhibitory co-stimulatory signals mediated by cytotoxic T lymphocyte antigen 4, (CTLA-4) expressed on activated T cells. The fully human monoclonal antibodies that are directed against human CTLA-4, ipilimumab (Medarex/Bristol-Myers Squibb) and CP-675,206 (Pfizer/Abgenix, now Amgen), have demonstrated activity against metastatic melanoma, hormone refractory prostate cancer and other malignancies. They have also uncovered unusual immune-related adverse events manifesting as self-limiting inflammatory reactions of the bowel, skin and pituitary. This article reviews preclinical development and data generated from Phase I, II and III studies with regard to the end points reported and immune-related adverse events. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|